The uncertainty over the future of health care has exacted a toll on the industry. ETFs like iShares Dow Jones US Healthcare Provider (IHF), Pharmaceutical HOLDRs (PPH) and iShares Biotechnology (IBB) all will be affected differently by changes in legislation.
One fact remains indisputable, however: America is getting older. As baby boomers reach old age, health care costs are expected to skyrocket. Whether or not new legislation transforms our existing system, costs likely will rise over the long term.
Picking individual drug companies or health care providers can be a tricky business, as outside factors like drug trials, lawsuits and legislation can weigh on results. ETFs are an effective way to mitigate the risk of investing in a single health care company by exposing investors to a basket of securities, rather than a hit-or-miss pick. The three main categories of health care ETFs are pharmaceutical, health care provider and biotechnology. Other, more specialized ETFs like iShares Dow Jones U.S. Medical Devices Index Fund (IHI) and international funds like WisdomTree International Health Care Sector Fund (DBR) offer different perspectives. Health care providers could have the most to lose in the battle for America's health care. iShares Dow Jones US Healthcare Provider (IHF) plummeted more than 40% in 2008 as investors tried to estimate the extent of health care reform. Top IHF components like UnitedHealth Group (UNH) and Medco Health Solutions (MHS) could be dramatically affected by a large shift toward a government "option" program. Health care price regulation could promote the use of generics at the expense of the pharmaceutical industry. Generic drugs have become more prevalent in recent years and have eaten into the profits of some of the large drugmakers. Pharmaceutical HOLDRs includes drugmakers like Abbott Labs (ABT) and Bristol-Myers Squibb (BMY).
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV